MX2013011333A - Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. - Google Patents

Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.

Info

Publication number
MX2013011333A
MX2013011333A MX2013011333A MX2013011333A MX2013011333A MX 2013011333 A MX2013011333 A MX 2013011333A MX 2013011333 A MX2013011333 A MX 2013011333A MX 2013011333 A MX2013011333 A MX 2013011333A MX 2013011333 A MX2013011333 A MX 2013011333A
Authority
MX
Mexico
Prior art keywords
combinations
akt
methods
mek inhibitor
inhibitor compounds
Prior art date
Application number
MX2013011333A
Other languages
English (en)
Spanish (es)
Inventor
Elizabeth Punnoose
Deepak Sampath
Brian Lee
Kui Lin
Michelle Nannini
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013011333A publication Critical patent/MX2013011333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013011333A 2011-04-01 2012-03-30 Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. MX2013011333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471038P 2011-04-01 2011-04-01
PCT/US2012/031716 WO2012135779A1 (en) 2011-04-01 2012-03-30 Combinations of akt and mek inhibitor compounds, and methods of use

Publications (1)

Publication Number Publication Date
MX2013011333A true MX2013011333A (es) 2014-04-16

Family

ID=46931964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011333A MX2013011333A (es) 2011-04-01 2012-03-30 Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.

Country Status (16)

Country Link
US (1) US9682082B2 (enExample)
EP (1) EP2694073B1 (enExample)
JP (1) JP6147246B2 (enExample)
KR (1) KR20140022053A (enExample)
CN (2) CN103841976A (enExample)
AU (1) AU2012236164A1 (enExample)
BR (1) BR112013025397A2 (enExample)
CA (1) CA2831932A1 (enExample)
ES (1) ES2688809T3 (enExample)
IL (1) IL228643A0 (enExample)
MX (1) MX2013011333A (enExample)
PL (1) PL2694073T3 (enExample)
RU (1) RU2013148817A (enExample)
SG (1) SG194047A1 (enExample)
TR (1) TR201815685T4 (enExample)
WO (1) WO2012135779A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086837A1 (en) * 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
MX2015007054A (es) * 2012-12-07 2016-01-12 Gen Hospital Corp Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
WO2014130923A2 (en) * 2013-02-25 2014-08-28 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
EP3041956B1 (en) 2013-09-05 2020-02-12 Memorial Sloan-Kettering Cancer Center Ddx43 as a biomarker of resistance to mek1/2 inhibitors
EP3897612A1 (en) 2018-12-19 2021-10-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor
IL296878A (en) * 2020-04-03 2022-12-01 Beigene Ltd Combined administration of miradmatinib and lipirafenib for use in the treatment of cancers
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2024255830A1 (zh) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗卵巢癌药物中的用途

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3885035A (en) 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) 1974-02-21 1976-06-29 Pfizer Inc. Piperazino quinazoline bronchodilators
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
JPS562968A (en) 1979-06-21 1981-01-13 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
US4749704A (en) 1985-03-07 1988-06-07 Sankyo Company Limited Cyclopenta[d]pyrimidine derivatives and use as antidepressants
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
WO1987004928A1 (fr) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
US4889856A (en) 1987-08-31 1989-12-26 Merck & Co., Inc. 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
US4871739A (en) 1987-01-21 1989-10-03 Merck & Co., Inc. Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
US4994464A (en) 1987-08-31 1991-02-19 Merck & Co., Inc. Piperazinylpyrimidines as β-adrenergic receptor blockers
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
PT664291E (pt) 1992-10-05 2000-11-30 Ube Industries Composto de pirimidina
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
ES2356886T3 (es) 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
IL144103A0 (en) 1999-01-07 2002-05-23 Warner Lambert Co Antiviral method using mek inhibitors
EP1140062B1 (en) 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
AU2482700A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 1-heterocycle substituted diarylamines
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
JP2002534497A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー スルホヒドロキサム酸およびスルホヒドロキサメートおよびｍｅｋ阻害剤としてのその使用
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
KR20020015379A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 엠이케이 억제제를 사용하는 만성 동통의 치료방법
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1365277A (zh) 1999-07-16 2002-08-21 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
JP2004507518A (ja) 2000-08-25 2004-03-11 ワーナー−ランバート・カンパニー・エルエルシー Ｎ−アリール−アントラニル酸及びその誘導体の製造法
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
EP1494676B1 (en) 2002-04-08 2013-05-08 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of akt activity
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc HEMMER OF ACT ACTIVITY
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
AU2003230367A1 (en) 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
CA2501365C (en) 2002-10-30 2011-05-31 Merck & Co., Inc. Inhibitors of akt activity
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
AR045445A1 (es) 2003-08-05 2005-10-26 Vertex Pharma Compuestos ihinibidores de canales ionicos regulados por voltaje
CA2534785A1 (en) 2003-08-12 2005-02-17 Robin Douglas Clark Tetrahydroquinazoline derivatives as cfr antagonists
US20070027156A1 (en) 2003-09-09 2007-02-01 Hisao Nakai Crf antagonists and heterobicyclic compounds
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
EP1682495A1 (en) 2003-10-21 2006-07-26 Warner-Lambert Company LLC Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
DE602005020611D1 (de) 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
US7879853B2 (en) 2004-06-28 2011-02-01 Bayer Schering Pharma Ag 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
US20060025074A1 (en) 2004-07-30 2006-02-02 Chih-Ming Liang Bluetooth-based headset
TWM266655U (en) 2004-09-23 2005-06-01 Blueexpert Technology Corp Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
WO2006094230A2 (en) 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
AR056691A1 (es) 2005-10-13 2007-10-17 Glaxo Group Ltd Derivados pirrolopirimidina como inhibidores de syk
CA2635541A1 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7718693B2 (en) 2006-07-06 2010-05-18 Glaxo Group Limited Receptor antagonists and their methods of use
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0613518D0 (en) 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
CA2699202C (en) * 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
RU2508110C2 (ru) * 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
UA101676C2 (uk) 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
WO2011038082A1 (en) * 2009-09-23 2011-03-31 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
WO2012135779A1 (en) 2012-10-04
EP2694073A1 (en) 2014-02-12
PL2694073T3 (pl) 2019-06-28
EP2694073A4 (en) 2014-09-03
TR201815685T4 (tr) 2018-11-21
ES2688809T3 (es) 2018-11-07
EP2694073B1 (en) 2018-08-08
US20140155372A1 (en) 2014-06-05
US9682082B2 (en) 2017-06-20
JP6147246B2 (ja) 2017-06-14
JP2014512355A (ja) 2014-05-22
IL228643A0 (en) 2013-12-31
SG194047A1 (en) 2013-11-29
NZ617243A (en) 2016-02-26
CN103841976A (zh) 2014-06-04
CA2831932A1 (en) 2012-10-04
BR112013025397A2 (pt) 2019-09-24
RU2013148817A (ru) 2015-05-10
AU2012236164A1 (en) 2013-11-21
KR20140022053A (ko) 2014-02-21
CN110433165A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12017502141A1 (en) Compounds and their methods of use
MY199894A (en) Prmt5 inhibitors and uses thereof
TN2012000401A1 (en) Heterocyclic compound
MX339873B (es) Inhibidores de serina/treonina cinasa.
PH12016500169A1 (en) Polymorph of syk inhibitors
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
PH12014500199A1 (en) Indazoles
MY184303A (en) Notch pathway signaling inhibitor compound
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013009527A3 (en) Factor ixa inhibitors
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain
MX338595B (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.
MX2013004421A (es) Compuestos inhibidores de catepsina s.
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
GEP20156398B (en) Indazoles
MX2014007398A (es) Derivado de 2,4-diamina-pirimidina como inhibidores de serina/treonina quinasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal